AI-Enriched Clinical Trials
Oncology
DevelopmentActive
Key Facts
About Noetik
Noetik is a private, pre-clinical stage biotech applying frontier AI and machine learning to oncology. The company has built a large-scale, multimodal tumor data collection and uses it to train foundation models capable of simulating the tumor microenvironment. Its platform aims to address key failures in oncology R&D by improving patient stratification for clinical trials, repositioning existing clinical-stage drugs, and discovering novel therapeutic targets. Backed by leading investors, Noetik is led by a seasoned team with deep expertise in computational biology, AI, drug development, and business strategy from companies like Recursion, Genentech, and Roche.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |